Institution statistics

PFIZER LIMITED - United Kingdom 

Ranking results:

Past rankings:
2019
Criterium:Position:
Overall Score:400-500
Total Number of Projects:200-300
2018
Criterium:Position:
Overall Score:800-900
Total Number of Projects:300-400
Networking Rank (Reputation):> 1000
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2011
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
Ranking timeline:

European project participation (2000-01-01 - 2020-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 34
As coordinator: 0
As participant: 34
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2020 0 51.725.694 0 3
2019 0 196.939.080 0 13
2018 0 103.838.674 0 7
2017 0 66.023.667 0 8
2016 0 14.080.000 0 2
2008 0 2.908.693 290.869 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
NOVARTIS PHARMA22
JANSSEN PHARMACEUTICA NV19
UCB BIOPHARMA15
ELI LILLY AND COMPANY LIMITED13
F HOFFMANNLA ROCHE12
SANOFIAVENTIS12
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT11
NOVO NORDISK10
TAKEDA DEVELOPMENT CENTRE EUROPE10
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD9
BAYER AKTIENGESELLSCHAFT8
KATHOLIEKE UNIVERSITEIT LEUVEN8
MERCK SHARP & DOHME CORP8
UNIVERSITAIR MEDISCH CENTRUM UTRECHT8
UNIVERSITY OF NEWCASTLE UPON TYNE8
ABBVIE INC7
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG7
EUROPEAN PATIENTS' FORUM7
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE7
KAROLINSKA INSTITUTE7
SANOFIAVENTIS RECHERCHE & DEVELOPPEMENT7
ACADEMISCH ZIEKENHUIS GRONINGEN6
ASTRAZENECA6
ASTRAZENECA AB6
BAYER6
CHARITE UNIVERSITAETSMEDIZIN BERLIN6
STICHTING KATHOLIEKE UNIVERSITEIT6
THE UNIVERSITY OF MANCHESTER6
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM5
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER5
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE5
MEDIZINISCHE UNIVERSITAET WIEN5
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN5
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL5
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE5
CHRISTIAN ALBRECHTS UNIVERSITAET ZU KIEL4
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE4
LEIDS UNIVERSITAIR MEDISCH CENTRUM4
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN4
SANOFIAVENTIS DEUTSCHLAND4
STICHTING VUMC4
TEVA PHARMACEUTICAL INDUSTRIES LIMITED4
THE UNIVERSITY OF LIVERPOOL4
UNIVERSITAET ZUERICH4
UNIVERSITY COLLEGE LONDON4
UNIVERSITY OF DUNDEE4
UPPSALA UNIVERSITET4
ACADEMIC MEDICAL CENTRE AMSTERDAM3
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM3
ACADEMISCH ZIEKENHUIS LEIDEN3
ALLERGAN LIMITED3
AMGEN LIMITED3
ANTAROS MEDICAL AB3
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS3
AUSTRIAN RESEARCH CENTERS SIEBERDORF3
BRISTOLMYERS SQUIBB COMPANY CORP3
EBERHARD KARLS UNIVERSITAET TUEBINGEN3
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK3
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE3
EUROPEAN CANCER PATIENT COALITION3
FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES3
FUJIFILM CELLULAR DYNAMICS INC3
FUNDACIO SANT JOAN DE DEU3
FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA3
GLAXOSMITHKLINE BIOLOGICALS3
H LUNDBECK AS3
INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE3
INSTITUT DE RECHERCHES SERVIER3
IXSCIENT LIMITED3
KING'S COLLEGE LONDON3
RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU3
SERVICIO ANDALUZ DE SALUD3
TARTU ULIKOOL3
THE UNIVERSITY OF SHEFFIELD3
UNIVERSITAETSKLINIKUM WUERZBURG KLINIKUM DER BAYERISCHEN JULIUSMAXIMILIANSUNIVERSITAT3
UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ3
UNIVERSITAT WIEN3
UNIVERSITATSKLINIKUM ERLANGEN3
UNIVERSITY OF BIRMINGHAM3
UNIVERSITY OF BOLOGNA3
UNIVERSITY OF COPENHAGEN3
UNIVERSITY OF GLASGOW3
BAYER PHARMA2
BIOMERIEUX2
CELGENE MANAGEMENT SARL2
CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY2
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS2
CONCENTRIS RESEARCH MANAGEMENT2
COVANCE LABORATORIES2
CSL BEHRING2
DEUTSCHES RHEUMAFORSCHUNGSZENTRUM BERLIN2
DREEM2
ELLEGAARD GOTTINGEN MINIPIGS AS2
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS2
EUROPEAN AIDS TREATMENT GROUP EV2
EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING2
EUROPEAN FEDERATION OF CROHN'S AND ULCERATIVE COLITIS ASSOCIATIONS2
EURORDIS EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION2
FOLKEHELSEINSTITUTTET2
FONDAZIONE PENTA FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV ANDRELATED DISEASES ONLUS2
Constancy:

Total number of partners:920

Partner loyalty:
Frequent Partner: (> 2 projects): 445
Rare Partner: 475

Frequent / Rare Partner Ratio: 0.94

Diversity:

Subjects: Diversity index:1
Categories:
Category:No:
BIOLOGICAL SCIENCES1

Project overview:

Start dateProjectacronymrolefundingpartners
2020-05-01EUbOPEN: Enabling and Unlocking biology in the OPEN EUbOPENparticipant27.935.00022
2020-01-01Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies ImmUniverseparticipant15.500.00026
2020-01-01PharmaLedger PharmaLedgerparticipant8.290.69428
2019-11-01Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases IDEA-FASTparticipant20.997.52346
2019-11-01EU Patient- cEntric clinicAl tRial pLatform EU-PEARLparticipant12.004.95336
2019-10-01Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies Immune-Imageparticipant15.000.00022
2019-09-01Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions 3TRparticipant40.273.19270
2019-09-01Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials Trials@Homeparticipant19.036.99831
2019-04-01Biomarkers in Atopic Dermatitis and Psoriasis BIOMAPparticipant10.500.00032
2019-04-01Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation ConcePTIONparticipant15.299.99153
2019-04-01Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement MOBILISE-Dparticipant25.395.89734
2019-03-01Neurotoxicity De-Risking in Preclinical Drug Discovery NeuroDeRiskparticipant5.331.00018
2019-03-01EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells EBiSC2participant4.599.64816
2019-02-01Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease TransBioLineparticipant13.999.99827
2019-01-01Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain IM2PACTparticipant9.000.00027
2019-01-01Vaccines and Infectious Diseases in the Ageing PopuLation VITALparticipant5.499.88224
2018-11-01European Health Data and Evidence Network EHDENparticipant14.105.75022
2018-09-01WEB-RADR 2 WEB-RADR 2participant1.168.75011
2018-09-01Ensuring the future of EUPATI beyond 2020 EFOEUPATIparticipant365.24312
2018-07-01Research empowerment on solute carriers (ReSOLUTE) ReSOLUTEparticipant12.000.00014
2018-05-01Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production iConsensusparticipant4.700.00019
2018-05-01conect4children (COllaborative Network for European Clinical Trials For Children) c4cparticipant67.000.00048
2018-03-01Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. PARADIGMparticipant4.498.93134
2017-11-01Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections COMBACTE-CDIparticipant2.312.30514
2017-11-01Liver Investigation: Testing Marker Utility in Steatohepatitis LITMUSparticipant15.797.88156
2017-10-01European Quality In Preclinical Data EQIPDparticipant4.495.52330
2017-09-01Rheuma Tolerance for Cure RTCureparticipant6.000.00020
2017-02-01Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 DO-ITparticipant3.549.83336
2017-01-01Imaging Biomarkers (IBs) for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment - Sofia ref.: 116106 IB4SD-TRISTANparticipant12.000.00021
2017-01-01REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019 RESCEUparticipant14.498.12518
2017-01-01ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064 ITCC-P4participant7.370.00021
2016-10-01Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFERparticipant6.000.00033
2016-04-01Psychiatric Ratings using Intermediate Stratified Markers - Sofia ref.: 115916 PRISMparticipant8.080.00023
2008-12-01Combating incontinence, from basic science to clinical practice INCOMBparticipant2.908.69310
Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum